Theranexus posted a sharp rise on the Paris Bourse on Friday, following the presentation of interim results judged to be "very encouraging" in the treatment of Batten disease.

At 11.15 a.m., the biopharmaceutical company's shares were up by over 8%, while the CAC Mid & Small index was up by 1.4% at the same time.

Interim results from the company's Phase 1/2 study showed no significant progression of motor symptoms after 12 months of treatment in the six patients monitored, all aged at least 17.

For Professor Gary Clark of Texas Children's Hospital in Houston, the study's principal investigator, this is a "first-of-its-kind" result in this indication.

Theranexus emphasizes that these efficacy and safety results after 12 months of treatment confirm those already obtained at six months, which were announced in mid-June.

The juvenile form of Batten disease is a rare and fatal genetic disorder of the nervous system, for which there is currently no treatment.

The first symptom of the juvenile form, progressive vision loss, appears between the ages of four and six, before the onset of cognitive, behavioral and motor difficulties.

The disease is always fatal - usually in late adolescence or early adulthood.

In a press release issued last night, Theranexus reported a proforma cash position of 7.8 million euros following the capital increase completed in July, giving it financial visibility of at least 12 months.

Copyright (c) 2023 CercleFinance.com. All rights reserved.